中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 1
Jan.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(1): 200-203

Clinical application of regional citrate anticoagulation in continuous renal replacement therapy for patients with liver failure

DOI: 10.3969/j.issn.1001-5256.2021.01.044

  • Department of Emergency, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

  • Received Date: 2020-07-16
  • Accepted Date: 2020-08-13
  • Published Date: 2021-01-20
    Abstract
  • In vitro anticoagulation is a key technique in continuous renal replacement therapy (CRRT), and heparin was once the preferred anticoagulant for CRRT, but its clinical application is limited due to the high risk of bleeding. Citrate, as a new regional anticoagulant, has received more and more attention and recommendation in recent years, but there are still controversies over its application in patients with liver failure. With reference to relevant literature in China and globally, this article reviews the metabolic characteristics and monitoring methods of regional citrate anticoagulation and its safety in CRRT for patients with liver failure.

     

    • FullText(HTML)
  • loading
    • References(34)
  • [1]
    EAST JM, CSERTI-GAZDEWICH CM, GRANTON JT. Heparin-induced thrombocytopenia in the critically ill patient[J]. Ches, 2018, 154(3): 678-690. DOI: 10.1016/j.chest.2017.11.039
    [2]
    KHWAJA A. KDIGO clinical practice guidelines for acute kidney injury[J]. Nephron Clin Pract, 2012, 120(4): c179-c184. http://www.karger.com/Article/Abstract/339789
    [3]
    CHEN XM, DING XQ, WANG Q, et al. Blood purification standard operating procedure (SOP)[M]. 2020 ed. Beijng: The People's Military Medical Association, 2020: 151. (in Chinese)

    陈香美, 丁小强, 王荣, 等. 血液净化标准操作规程[M]. 2020版.北京:人民军医出社, 2020: 151.
    [4]
    HARTMANN J, STROBL K, FICHTINGER U, et al. In vitro investigations of citrate clearance with different dialysis filters[J]. Int J Artif Organs, 2012, 35(5): 352-359. DOI: 10.5301/ijao.5000098
    [5]
    MARIANO F, MORSELLI M, BERGAMO D, et al. Blood and ultrafiltrate dosage of citrate as a useful and routine tool during continuous venovenous haemodiafiltration in septic shock patients[J]. Nephrol Dial Transplant, 2011, 26(12): 3882-3888. DOI: 10.1093/ndt/gfr106
    [6]
    HUANG YL, CHEN YH, YUAN L, et al. Application of local anticoagulation with citrate in hemodialysis of patients with high risk of bleeding tendency[J]. J Clin Exp Med, 2019, 18(18): 2002-2005. (in Chinese) DOI: 10.3969/j.issn.1671-4695.2019.18.029

    黄艳玲, 陈永华, 袁利, 等. 高危出血倾向患者血液透析中局部枸橼酸抗凝的应用[J]. 临床和实验医学杂志, 2019, 18(18): 2002-2005. DOI: 10.3969/j.issn.1671-4695.2019.18.029
    [7]
    SHUM HP, YAN WW, CHAN TM. Risks and benefits of citrate anticoagulation for continuous renal replacement therapy[J]. Hong Kong Med J, 2015, 21(2): 149-154. http://www.ncbi.nlm.nih.gov/pubmed/25477338
    [8]
    ZHANG W, BAI M, YU Y, et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: A systematic review and meta-analysis[J]. Crit Care, 2019, 23(1): 22. DOI: 10.1186/s13054-019-2317-9
    [9]
    GAO J, WANG F, WANG Y, et al. A mode of CVVH with regional citrate anticoagulation compared to no anticoagulation for acute kidney injury patients at high risk of bleeding[J]. Sci Rep, 2019, 9(1): 6607. DOI: 10.1038/s41598-019-42916-1
    [10]
    LEUNG AK, SHUM HP, CHAN KC, et al. A retrospective review of the use of regional citrate anticoagulation in continuous venovenous hemofiltration for critically ill patients[J]. Crit Care Res Pract, 2013, 2013: 349512. DOI: 10.1155/2013/349512
    [11]
    KLINGELE M, STADLER T, FLISER D, et al. Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction[J]. Crit Care, 2017, 21(1): 294. DOI: 10.1186/s13054-017-1870-3
    [12]
    BURRY LD, TUNG DD, HALLETT D, et al. Regional citrate anticoagulation for PrismaFlex continuous renal replacement therapy[J]. Ann Pharmacother, 2009, 43(9): 1419-1425. DOI: 10.1345/aph.1M182
    [13]
    SPONHOLZ C, BAYER O, KABISCH B, et al. Anticoagulation strategies in venovenous hemodialysis in critically ill patients: A five-year evaluation in a surgical intensive care unit[J]. Sci World J, 2014, 2014: 808320. http://pubmedcentralcanada.ca/pmcc/articles/PMC4274656/
    [14]
    KALB R, KRAM R, MORGERA S, et al. Regional citrate anticoagulation for high volume continuous venovenous hemodialysis in surgical patients with high bleeding risk[J]. Ther Apher Dial, 2013, 17(2): 202-212. DOI: 10.1111/j.1744-9987.2012.01101.x
    [15]
    ZHENG Y, XU Z, ZHU Q, et al. Citrate pharmacokinetics in critically ill patients with acute kidney injury[J]. PLoS One, 2013, 8(6): e65992. DOI: 10.1371/journal.pone.0065992
    [16]
    RODRIGUEZ K, SRIVATHS PR, TAL L, et al. Regional citrate anticoagulation for continuous renal replacement therapy in pediatric patients with liver failure[J]. PLoS One, 2017, 12(8): e0182134. DOI: 10.1371/journal.pone.0182134
    [17]
    NING QQ, GAO Y, DUAN ML, et al. Efficacy and safety of regional citrate anticoagulation in patients with severe liver diseases and acute kidney injury[J]. J Clin Hepatol, 2020, 36(5): 1055-1058. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.05.021

    宁琪琪, 高原, 段美丽, 等. 局部枸橼酸抗凝在接受连续性肾脏替代治疗的肝病合并急性肾损伤中的应用效果观察[J]. 临床肝胆病杂志, 2020, 36(5): 1055-1058. DOI: 10.3969/j.issn.1001-5256.2020.05.021
    [18]
    SCHULTHEIβ C, SAUGEL B, PHILLIP V, et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: A prospective observational study[J]. Crit Care, 2012, 16(4): r162. DOI: 10.1186/cc11485
    [19]
    LAHMER T, MESSER M, RASCH S, et al. Sustained low-efficiency dialysis with regional citrate anticoagulation in medical intensive care unit patients with liver failure: A prospective study[J]. J Crit Care, 2015, 30(5): 1096-1100. DOI: 10.1016/j.jcrc.2015.06.006
    [20]
    WEINBERG JM, VENKATACHALAM MA, ROESER NF, et al. Mitochondrial dysfunction during hypoxia/reoxygenation and its correction by anaerobic metabolism of citric acid cycle intermediates[J]. Proc Natl Acad Sci U S A, 2000, 97(6): 2826-2831. DOI: 10.1073/pnas.97.6.2826
    [21]
    FELDKAMP T, WEINBERG JM, HÖRBELT M, et al. Evidence for involvement of nonesterified fatty acid-induced protonophoric uncoupling during mitochondrial dysfunction caused by hypoxia and reoxygenation[J]. Nephrol Dial Transplant, 2009, 24(1): 43-51. http://www.ncbi.nlm.nih.gov/pubmed/18678559
    [22]
    YAO YH, GAN JH, ZHAO WF. Effect of plasma exchange combined with continuous renal replacement therapy on the prognosis of patients with HBV-related acute-on-chronic liver failure and acute kidney injury[J]. J Clin Hepatol, 2019, 35(5): 1065-1069. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.05.026

    姚运海, 甘建和, 赵卫峰. 血浆置换联合持续性肾脏替代治疗对HBV相关慢加急性肝衰竭合并急性肾损伤患者预后的影响[J]. 临床肝胆病杂志, 2019, 35(5): 1065-1069. DOI: 10.3969/j.issn.1001-5256.2019.05.026
    [23]
    BROMAN M, KLARIN B, SANDIN K, et al. Simplified citrate anticoagulation for CRRT without calcium replacement[J]. ASAIO J, 2015, 61(4): 437-442. DOI: 10.1097/MAT.0000000000000226
    [24]
    TOLWANI A, WILLE KM. Advances in continuous renal replacement therapy: Citrate anticoagulation update[J]. Blood Purif, 2012, 34(2): 88-93. DOI: 10.1159/000342378
    [25]
    LINK A, KLINGELE M, SPEER T, et al. Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients[J]. Crit Care, 2012, 16(3): r97. DOI: 10.1186/cc11363
    [26]
    WANG J, YU Y, SUN SQ, et al. Application of continuous renal replacement therapy with regional citrate anticoagulation in patients at high risk of bleeding[J]. Chin J Blood Purificat, 2015, 14(7): 404-407. (in Chinese) DOI: 10.3969/j.issn.1671-4091.2015.07.006

    王佳, 余毅, 孙淑清, 等. 局部枸橼酸体外抗凝在高危出血风险患者持续肾脏替代治疗中的应用[J]. 中国血液净化, 2015, 14(7): 404-407. DOI: 10.3969/j.issn.1671-4091.2015.07.006
    [27]
    KHADZHYNOV D, SCHELTER C, LIEKER I, et al. Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation[J]. J Crit Care, 2014, 29(2): 265-271. DOI: 10.1016/j.jcrc.2013.10.015
    [28]
    HILL S, CREIGHTON E, WALTER E. The safety of regional citrate anticoagulation in renal replacement therapy[J]. J Intensive Care Soc, 2018, 19(1): 86. DOI: 10.1177/1751143717735749
    [29]
    HONORE PM, de BELS D, REDANT S, et al. Inducible metabolic pathway for citrate metabolism in case of major liver dysfunction: Fact or fiction?[J]. Crit Care, 2019, 23(1): 166. DOI: 10.1186/s13054-019-2432-7
    [30]
    HONORE PM, MUGISHA A, DAVID C, et al. In severe liver disease, citrate can be used safely: The question remains-by which mechanism[J]. Crit Care, 2020, 24(1): 63. DOI: 10.1186/s13054-020-2801-2
    [31]
    DEVAUCHELLE P, PAGE M, BRUN P, et al. Continuous haemodialysis with citrate anticoagulation in patients with liver failure: Three cases[J]. Ann Fr Anesth Reanim, 2012, 31(6): 543-546. DOI: 10.1016/j.annfar.2012.01.036
    [32]
    SLOWINSKI T, MORGERA S, JOANNIDIS M, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: The Liver Citrate Anticoagulation Threshold (L-CAT) observational study[J]. Crit Care, 2015, 19: 349. DOI: 10.1186/s13054-015-1066-7
    [33]
    YU Y, PENG S, CEN Z, et al. Applying regional citrate anticoagulation in continuous renal replacement therapy for acute kidney injury patients with acute liver dysfunction: A retrospective observational study[J]. Kidney Blood Press Res, 2018, 43(4): 1065-1074. DOI: 10.1159/000491057
    [34]
    BALOGUN RA, TURGUT F, CALDWELL S, et al. Regional citrate anticoagulation in critically ill patients with liver and kidney failure[J]. J Nephrol, 2012, 25(1): 113-119. DOI: 10.5301/JN.2011.8363
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (486) PDF downloads(36) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return